"Immunomodulators Not Necessary With Long-Term Stelara Therapy In Crohn’s" -Alex Young
Concomitant immunomodulatory use is not necessary with Stelara therapy for Crohn’s disease, according to long-term data from the IM-UNITI LTE study presented at the American College of Gastroenterology Annual Meeting. “The ongoing immunity long-term extension study evaluates the efficacy and safety of subcutaneous ustekinumab through approximately five years of treatment,” Bruce E. Sands, MD, chief of the division of gastroenterology at the Mount Sinai Health System, said during his presentation. “Results through week 44 of maintenance previously demonstrated no apparent benefit of concomitant immunomodulators on efficacy, drug levels or immunogenicity.” Dr. Sands said their findings support the notion that concomitant IMM use with ustekinumab is not necessary.
- Bruce E. Sands, MD, Professor, Medicine, Gastroenterology, Icahn School of Medicine at Mount Sinai, Chief, Division of Gastroenterology, Mount Sinai Health System